课题基金 / 基金详情

RR&D Gordon Mansfield Spinal Cord Injury Consortium

RR&D Gordon Mansfield Spinal Cord Injury Consortium
RR
批准号:
10538563
负责人:
MARK H. TUSZYNSKI
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-07-01 至 2025-12-31

项目摘要

项目成果

MARK H. TUSZYNSKI的其他基金

相似基金

相关文献

中文摘要
翻译
本项目旨在开发一种神经干细胞(NSC)疗法来修复受损的脊髓 支持功能恢复。在拟议的工作中,我们的目标是将这一计划推进到一个 IND启用阶段。此外,我们的目标是继续开发和优化潜在的干细胞 脊髓损伤(SCI)的治疗,通过检查创新的康复和 脊髓神经调节策略与神经干细胞疗法, 干细胞介导的功能恢复。最后,我们的目标是投入大量精力, NSC在慢性SCI中的疗效。 这项工作的重点是人类神经干细胞来自联邦“批准”的人类胚胎干细胞 细胞(ESC)系,H9 ESC系。我们在此提出的研究将主要用于临床 相关脊髓损伤挫伤模型。由外部研究者独立复制 这个科学家联盟将进行。 值得注意的是,这是一个在研究脊髓损伤的领先实验室之间的密切合作。 脊髓损伤,包括圣地亚哥VA医疗中心和UCSD的Tuszynski小组 (包括Rosenzweig博士,Lu博士和Brock博士); San Francisco的Beattie/Bresnahan/Ferguson小组 弗朗西斯科VA医疗中心和UCSF;加州大学欧文分校的Reinkensmeyer实验室; 加州大学洛杉矶分校;位于加州大学戴维斯分校的加州国家灵长类动物研究中心;以及Courtine 瑞士联邦理工学院的实验室。实验是集体设计的 并由该联盟执行,这是SCI研究中前所未有的努力,以推动该领域的发展 通过在共同进行的实验上的密切合作和互动。自始至终,这 该项目将受益于合作者之间的信息自由交流。
英文摘要
This project aims to develop a neural stem cell (NSC) therapy to repair the injured spinal cord and support functional recovery. In the proposed work, we aim to advance this program to an IND-enabling stage. Moreover, we aim to continue to develop and optimize potential stem cell therapies for spinal cord injury (SCI) by examining combinations of innovative rehabilitation and spinal cord neuromodulation strategies with neural stem cell therapies to potentially amplify stem cell-mediated recovery of function. Finally, we aim to invest substantial effort to assess NSC efficacy in chronic SCI. This work focuses on human NSCs derived from a federally “approved” human embryonic stem cell (ESC) line, the H9 ESC line. The studies we propose herein will primarily use clinically relevant spinal cord injury contusion models. Independent replication by an investigator outside this consortium of scientists will be conducted. Notably, this is an intensely collaborative effort among leading laboratories researching spinal cord injury, including the Tuszynski group at the San Diego VA Medical Center and UCSD (includes Drs. Rosenzweig, Lu and Brock); the Beattie/Bresnahan/Ferguson group at the San Francisco VA Medical Center and UCSF; the Reinkensmeyer lab at UC Irvine; the Havton lab at UCLA; the California National Primate Research Center located at UC Davis; and the Courtine lab at the Swiss Federal Institute of Technology. Experiments have been collectively designed and performed by this consortium, an unprecedented effort in SCI research to advance the field through close collaboration and interaction on jointly performed experiments. Throughout, this project will benefit from a free exchange of information among the collaborators.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.stemcr.2017.04.004
发表时间: 2017-06-06
期刊: Stem cell reports
影响因子: 5.9
作者: [Adler AF, Lee-Kubli C, Kumamaru H, Kadoya K, Tuszynski MH]
通讯作者: Tuszynski MH
Advancing human neural progenitor cells (hNPCs) to FDA IND approval
  • 批准号:
    10642228
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2023
  • 负责人:
    MARK H. TUSZYNSKI
  • 依托单位:
The Primate Corticospinal Connectome and Transcriptome - Supplement
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
海外基金